The carcinoembryonic antigen market size has grown rapidly in recent years. It will grow from $1.07 billion in 2023 to $1.22 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The growth observed in the historic period can be attributed to several factors, including the global prevalence of cancer, an aging population, awareness campaigns about cancer, development in healthcare infrastructure, and favorable reimbursement policies.
The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.02 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. In the forecast period, growth is expected to be driven by a focus on early detection and prevention of cancer, the expansion of cancer screening programs, increased patient demand for personalized medicine, and a growing need for minimally invasive diagnostic procedures. Major trends anticipated during this time include an increased adoption of personalized medicine, advancements in diagnostic platforms leveraging artificial intelligence and big data, collaborations and partnerships in the healthcare industry, and the impact of regulatory approvals and reimbursement policies.
The growth of the carcinoembryonic antigen market is expected to be driven by an increase in cancer incidence. Cancer, characterized by abnormal cell growth and spread, is on the rise due to various factors such as lifestyle choices, environmental pollution, genetic factors, and an aging population. Carcinoembryonic antigen (CEA) serves as a tumor marker in cancer management, aiding in monitoring disease progression and treatment efficacy. For instance, the World Health Organization (WHO) reported in February 2024 that the predicted number of new cancer cases in 2050 is around 35 million, marking a 77% increase from the estimated 20 million cases in 2022. This surge in cancer cases is a key driver for the carcinoembryonic antigen market's growth.
Leading companies in the carcinoembryonic antigen market are focusing on developing advanced tumor marker tests to streamline diagnostics and improve diagnostic offerings. These tests detect specific substances in the body that may indicate the presence of cancer. For example, Boditech Med introduced the ichroma Tumor triple-M diagnostic kit in October 2021, approved by the Ministry of Food and Drug Safety in South Korea. This kit can measure three tumor markers - prostate-specific antigen (PSA), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) - simultaneously, aiding in early diagnosis of cancers such as prostate, liver, and colon cancer. The kit's ability to provide rapid results within 15 minutes using whole blood offers cost and time-saving benefits.
In December 2023, Danaher Corporation acquired Abcam Limited to enhance its capabilities and expand its market presence in life sciences and diagnostics. Abcam Limited, a producer and distributor of protein research tools including recombinant human carcinoembryonic antigen CEA protein, contributes to Danaher's offerings in the field.
Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilient Technologies, Inc., Beckman Coulter Inc., bioMérieux SA, Quidel Corporation, Ortho Clinical Diagnostics, Abcam plc, RayBiotech Inc., Creative Diagnostics, Lee Biosolutions Inc., Hytest Ltd., Prospec-Tany Technogene Ltd, Boster Biological Technology, Metropolis Healthcare.
North America was the largest region in the carcinoembryonic antigen market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the carcinoembryonic antigen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Carcinoembryonic antigen (CEA) is a glycoprotein primarily involved in cell adhesion, commonly found in embryonic tissues and various carcinomas. In clinical practice, CEA serves as a tumor marker crucial for diagnosing, monitoring, and managing cancer, especially colorectal cancer. It aids in evaluating the efficacy of cancer treatments and is used for post-treatment monitoring to detect signs of cancer recurrence.
The main types of carcinoembryonic antigen tests include molecular tests and serology tests. Molecular tests for CEA involve analyzing genetic material, such as DNA or RNA, to measure CEA levels. These tests can be applied across genders, including males and females, and are used in various cancer types such as gastrointestinal cancer, colorectal cancer, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, ovarian cancer, among others. End-users of these tests include hospitals, diagnostic centers, cancer centers, and research institutes.
The carcinoembryonic antigen market research report is one of a series of new reports that provides carcinoembryonic antigen market statistics, including the carcinoembryonic antigen industry global market size, regional shares, competitors with the carcinoembryonic antigen market share, detailed carcinoembryonic antigen market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoembryonic antigen industry. These carcinoembryonic antigen market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The carcinoembryonic antigen market consists of sales of diagnostic kits or assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.02 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. In the forecast period, growth is expected to be driven by a focus on early detection and prevention of cancer, the expansion of cancer screening programs, increased patient demand for personalized medicine, and a growing need for minimally invasive diagnostic procedures. Major trends anticipated during this time include an increased adoption of personalized medicine, advancements in diagnostic platforms leveraging artificial intelligence and big data, collaborations and partnerships in the healthcare industry, and the impact of regulatory approvals and reimbursement policies.
The growth of the carcinoembryonic antigen market is expected to be driven by an increase in cancer incidence. Cancer, characterized by abnormal cell growth and spread, is on the rise due to various factors such as lifestyle choices, environmental pollution, genetic factors, and an aging population. Carcinoembryonic antigen (CEA) serves as a tumor marker in cancer management, aiding in monitoring disease progression and treatment efficacy. For instance, the World Health Organization (WHO) reported in February 2024 that the predicted number of new cancer cases in 2050 is around 35 million, marking a 77% increase from the estimated 20 million cases in 2022. This surge in cancer cases is a key driver for the carcinoembryonic antigen market's growth.
Leading companies in the carcinoembryonic antigen market are focusing on developing advanced tumor marker tests to streamline diagnostics and improve diagnostic offerings. These tests detect specific substances in the body that may indicate the presence of cancer. For example, Boditech Med introduced the ichroma Tumor triple-M diagnostic kit in October 2021, approved by the Ministry of Food and Drug Safety in South Korea. This kit can measure three tumor markers - prostate-specific antigen (PSA), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) - simultaneously, aiding in early diagnosis of cancers such as prostate, liver, and colon cancer. The kit's ability to provide rapid results within 15 minutes using whole blood offers cost and time-saving benefits.
In December 2023, Danaher Corporation acquired Abcam Limited to enhance its capabilities and expand its market presence in life sciences and diagnostics. Abcam Limited, a producer and distributor of protein research tools including recombinant human carcinoembryonic antigen CEA protein, contributes to Danaher's offerings in the field.
Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilient Technologies, Inc., Beckman Coulter Inc., bioMérieux SA, Quidel Corporation, Ortho Clinical Diagnostics, Abcam plc, RayBiotech Inc., Creative Diagnostics, Lee Biosolutions Inc., Hytest Ltd., Prospec-Tany Technogene Ltd, Boster Biological Technology, Metropolis Healthcare.
North America was the largest region in the carcinoembryonic antigen market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the carcinoembryonic antigen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Carcinoembryonic antigen (CEA) is a glycoprotein primarily involved in cell adhesion, commonly found in embryonic tissues and various carcinomas. In clinical practice, CEA serves as a tumor marker crucial for diagnosing, monitoring, and managing cancer, especially colorectal cancer. It aids in evaluating the efficacy of cancer treatments and is used for post-treatment monitoring to detect signs of cancer recurrence.
The main types of carcinoembryonic antigen tests include molecular tests and serology tests. Molecular tests for CEA involve analyzing genetic material, such as DNA or RNA, to measure CEA levels. These tests can be applied across genders, including males and females, and are used in various cancer types such as gastrointestinal cancer, colorectal cancer, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, ovarian cancer, among others. End-users of these tests include hospitals, diagnostic centers, cancer centers, and research institutes.
The carcinoembryonic antigen market research report is one of a series of new reports that provides carcinoembryonic antigen market statistics, including the carcinoembryonic antigen industry global market size, regional shares, competitors with the carcinoembryonic antigen market share, detailed carcinoembryonic antigen market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoembryonic antigen industry. These carcinoembryonic antigen market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The carcinoembryonic antigen market consists of sales of diagnostic kits or assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Carcinoembryonic Antigen Market Characteristics3. Carcinoembryonic Antigen Market Trends and Strategies32. Global Carcinoembryonic Antigen Market Competitive Benchmarking33. Global Carcinoembryonic Antigen Market Competitive Dashboard34. Key Mergers and Acquisitions in the Carcinoembryonic Antigen Market
4. Carcinoembryonic Antigen Market - Macro Economic Scenario
5. Global Carcinoembryonic Antigen Market Size and Growth
6. Carcinoembryonic Antigen Market Segmentation
7. Carcinoembryonic Antigen Market Regional and Country Analysis
8. Asia-Pacific Carcinoembryonic Antigen Market
9. China Carcinoembryonic Antigen Market
10. India Carcinoembryonic Antigen Market
11. Japan Carcinoembryonic Antigen Market
12. Australia Carcinoembryonic Antigen Market
13. Indonesia Carcinoembryonic Antigen Market
14. South Korea Carcinoembryonic Antigen Market
15. Western Europe Carcinoembryonic Antigen Market
16. UK Carcinoembryonic Antigen Market
17. Germany Carcinoembryonic Antigen Market
18. France Carcinoembryonic Antigen Market
19. Italy Carcinoembryonic Antigen Market
20. Spain Carcinoembryonic Antigen Market
21. Eastern Europe Carcinoembryonic Antigen Market
22. Russia Carcinoembryonic Antigen Market
23. North America Carcinoembryonic Antigen Market
24. USA Carcinoembryonic Antigen Market
25. Canada Carcinoembryonic Antigen Market
26. South America Carcinoembryonic Antigen Market
27. Brazil Carcinoembryonic Antigen Market
28. Middle East Carcinoembryonic Antigen Market
29. Africa Carcinoembryonic Antigen Market
30. Carcinoembryonic Antigen Market Competitive Landscape and Company Profiles
31. Carcinoembryonic Antigen Market Other Major and Innovative Companies
35. Carcinoembryonic Antigen Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Carcinoembryonic Antigen Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on carcinoembryonic antigen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for carcinoembryonic antigen? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carcinoembryonic antigen market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Test Type: Molecular Tests; Serology Tests2) By Gender: Male; Female
3) By Application: Gastrointestinal Cancer; Colorectal Cancer; Pancreatic Cancer; Breast Cancer; Lung Cancer; Thyroid Cancer; Ovarian Cancer; Other Applications
4) By End User: Hospitals; Diagnostic Centers; Cancer Centers; Research And Academic Institutes
Key Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Siemens Healthineers
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Merck KGaA
- Siemens Healthineers
- Laboratory Corporation of America Holdings
- Quest Diagnostics
- Agilient Technologies, Inc.
- Beckman Coulter Inc.
- bioMérieux SA
- Quidel Corporation
- Ortho Clinical Diagnostics
- Abcam plc
- RayBiotech Inc.
- Creative Diagnostics
- Lee Biosolutions Inc.
- Hytest Ltd.
- Prospec-Tany Technogene Ltd
- Boster Biological Technology
- Metropolis Healthcare
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | August 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 1.22 Billion |
Forecasted Market Value ( USD | $ 2.02 Billion |
Compound Annual Growth Rate | 13.5% |
Regions Covered | Global |
No. of Companies Mentioned | 20 |